Arranta Bio provides contract development and manufacturing services to pioneering innovators working on new therapies targeting diseases linked to the human microbiome.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility.
Our aim is to support the pioneers in the development of healthcare therapies based on live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.
Over a 10-year period, Captozyme produced over 125 species and amassed a deep understanding of the manufacturing needs for live biopharmaceuticals, whether that be obligate, facultative or microaerophilic organisms.
Arranta Bio was formed in May 2019 and merged with Captozyme in November 2019, advancing our goal to support clients from early-stage process development through cGMP clinical supply to commercialization.Learn More
There has never been greater acceleration in scientific understanding of gut microbiota. Arranta Bio is proud to serve pioneering innovators on this exciting frontier.Learn More
Building on the foundation of Captozyme, Arranta Bio offers development and cGMP manufacture of live biotherapeutic products (LBPs) for clinical and commercial supply.Learn More
We’re always open to engaging with people interested in our company or the microbiome therapy market in general.
We look forward to hearing from you.